Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Tzield (teplizumab-mzwv) targeting young children with stage 2 …
Copyright MatchingDonors.com © 2026 All rights reserved.
Daily Diabetes News is published by MatchingDonors.com.